Skip to main content

Acumen Pharmaceuticals, Inc.

corporate_fare Company Profile

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ·Life Sciences·CIK 0001576885

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a disease-modifying approach for Alzheimer's disease (AD). AD is a progressive neurodegenerative disease affecting approximately seven million people in the United States and 55 million worldwide. In 2022, it was the sixth-leading cause of death for individuals aged 65 and older in the United States. Without effective treatments, the U.S. patient population is projected to reach 13 million by 2050, with healthcare costs nearing $1 trillion. The company's scientific founders conducted pioneering research on soluble amyloid-beta oligomers (AßOs), which are distinct from Aß monomers and amyloid plaques and are increasingly recognized as a primary toxin in AD pathology. Acumen Pharmaceuticals is currently advancing sabirnetug (ACU193), a targeted immunotherapy drug candidate, in its Phase 2 ALTITUDE-AD clinical trial. Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2) monoclonal antibody (mAb) designed to selectively target AßOs. It has shown functional and protective effects in in vitro assays and demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic mouse models for AD. It also demonstrated safety and pharmacologic activity in human AD patients during the Phase 1 INTERCEPT-AD clinical trial, with results announced in July 2023.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ABOS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Acumen Pharma Secures $35.75M in Private Placement at 17.5% Discount, Funds EBD Program
  • Acumen Secures $35.75M Private Placement, Reveals Strong Preclinical Data for Alzheimer's EBD Program
  • Acumen Pharmaceuticals Highlights Strong Sabirnetug Phase 1 Data and EBD Program Advancement in Updated Presentation

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$121.33M
Diluted EPS
-$2.00
Op. Cash Flow
-$115.54M
Free Cash Flow
-$115.63M
Operating Income
-$123.83M
Cash & Equivalents
$53.99M
Total Debt
$31.16M
Debt / Equity
0.44×
Shares Outstanding
60.58M sh
Source: 10-K · filed 2026-03-26 · accession 0001628280-26-021413
$0.1757 -5.79% today
52-week range · as of 2026-11-05 $0.1757 – $3.6
Market cap
$13.49M
Volume
2.7M (0.5× avg)
3-mo avg 5.3M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABOS - Filings & News (Page 2)

ABOS
Mar 16, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $0.1757 info
Change: -$3.82 (-96%) info
Market Cap: $13.489M info
ABOS
Mar 16, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.60
Real-time Price: $0.1757 info
Change: -$3.42 (-95%) info
Market Cap: $13.489M info
ABOS
Jan 12, 2026, 8:33 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.76
Real-time Price: $0.1757 info
Change: -$1.58 (-90%) info
Market Cap: $13.489M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets